Report Details:
15 Companies Covered
146 Pages
Closed System Drug Transfer Device (CSTD) Market to Progress at a CAGR of 10.17% through the Forecast Period 2025-2035
Closed System Drug Transfer Device Market Overview
The global closed system drug transfer device (CSTD) market is projected to reach USD 4.98 billion by 2035, expanding from USD 1.71 billion in 2024 at a robust CAGR of 10.24% during the forecast period.
The market growth is primarily driven by the rising prevalence of cancer worldwide, increasing use of hazardous drugs in healthcare facilities, and the growing emphasis on occupational safety for healthcare workers.
Closed system drug transfer devices are engineered to prevent the escape of hazardous drug vapors, aerosols, or droplets during preparation, administration, and disposal. Their adoption has gained significant momentum as awareness of the risks associated with cytotoxic drug exposure continues to grow.
In addition, stringent regulatory standards, such as those set by the U.S. Occupational Safety and Health Administration (OSHA) and National Institute for Occupational Safety and Health (NIOSH), are reinforcing the widespread integration of CSTDs in hospitals and oncology centers globally.
The ongoing advancements in device design, including user-friendly interfaces and compatibility with multiple drug delivery systems, are expected to further support market expansion.
Moreover, the growing focus on standardizing safe handling practices and the introduction of cost-efficient CSTDs are fueling adoption across both developed and emerging healthcare systems.
Segment Insights
The closed system drug transfer device market is segmented by type, component, closing mechanism, technology, and end user. Based on type, the membrane-to-membrane systems category held the largest market share in 2022 and is expected to maintain its dominance throughout the forecast period.
The efficacy and efficiency of such systems proved to be a game-changer for the segment, which fueled its popularity. The needless systems, however, are gaining more traction as consumers have started preferring non-invasive treatments.
By component, the vial access device category accounted for the largest share in 2022. Increasing investments in product innovation and improved design compatibility are supporting the segment’s growth.
Meanwhile, accessories such as syringe safety devices are expected to witness steady demand, supported by rising procedural volumes in cancer treatment.
In the closing membrane segment, the push-to-turn system category held the highest market share, owing to the ease of use of devices and systems. The click-to-lock system category is expected to propagate faster through the forecast period due to innovation in the design of the system.
In terms of technology, diaphragm-based devices are expected to register substantial growth during the forecast period, attributed to their effective containment and reduced risk of hazardous drug exposure.
Based on end user, hospitals and clinics represented the dominant segment in 2022, accounting for a significant share of global revenue. The rise in chemotherapy administration in hospital settings, coupled with growing awareness about worker safety, has driven the demand for CSTDs.
Oncology centers are projected to exhibit strong growth, supported by increasing adoption of advanced protective equipment and regulatory compliance requirements.
Regional Insights
North America held the dominant share of 45% in the global closed system drug transfer device market in 2022. The region’s growth is driven by stringent occupational safety regulations, the high incidence of cancer, and widespread awareness about hazardous drug exposure.
The United States remained a key contributor, supported by a strong healthcare infrastructure and rapid adoption of technologically advanced CSTDs.
Europe captured approximately 30% of the market share in 2022, with strong demand from hospital and oncology departments. Countries such as Germany, France, and the UK are investing heavily in safety compliance systems, further boosting market penetration.
The Asia-Pacific (APAC) region accounted for around 20% of the market share in 2022 and is expected to experience the fastest growth during the forecast period. The expansion is driven by rising cancer incidence, increasing healthcare investments, and the adoption of international safety standards across countries such as Japan, China, and India.
The Middle East and Africa (MEA) region represented around 5% of the market share in 2022. Growing awareness about occupational safety, coupled with the establishment of advanced healthcare facilities in the UAE and Saudi Arabia, is fostering gradual market development in the region.
Key Players
Leading players operating in the global closed system drug transfer device market include Becton, Dickinson and Company (US), ICU Medical, Inc. (US), Equashield LLC (Israel), Corvida Medical (US), Simplivia Healthcare (Israel), B. Braun Melsungen AG (Germany), and Teva Pharmaceutical Industries Ltd. (Israel).
These companies are actively investing in product innovation, partnerships, and global expansion strategies to enhance product performance and availability. The focus remains on improving device ergonomics, material safety, and compatibility with a wide range of drug delivery systems.
Industry Developments
- In December 2023, Equashield launched an advanced CSTD solution designed for enhanced safety and efficiency in oncology drug handling.
- In October 2023, Equashield introduced a next-generation closed system designed for improved compatibility with automated compounding systems, further strengthening its product portfolio.
These recent developments highlight the increasing focus on technological innovation, occupational safety, and compliance-driven product evolution within the CSTD industry.
Key Findings
- The global closed system drug transfer device market will grow from USD 1.71 billion in 2024 to USD 4.98 billion by 2035, at a CAGR of 10.24%.
- North America led the market with a 45% share, followed by Europe (30%), Asia-Pacific (20%), and MEA (5%).
- Diaphragm-based devices dominated the market, supported by superior safety and containment features.
- Hospitals remained the leading end users, driven by chemotherapy administration and regulatory compliance.
- Technological innovations and regulatory initiatives are shaping the global CSTD adoption landscape.